Personal Information
Entreprise/Lieu de travail
London, United Kingdom United Kingdom
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
ohe.org
À propos
OHE provides authoritative resources and analyses in health economics, health policy and health statistics through independent research and consultancy. Our work informs decision making about health care, life sciences and the pharmaceutical industry, tackling policy and strategic issues affecting the present and shaping the future. We work closely with stakeholders, clients and external experts to develop important new policy insights, define strategies and identify optimal choices.
Mots-clés
health economics
hta
pharmaceuticals
uk
medicines
health care
innovation
eq-5d
nhs
pricing
biotechnology and pharmaceuticals
nice
htai
pharmaceutical industry
r&d
england
ohe
adrian towse
ispor
cancer
health technology assessment
reimbursement
qaly
europe
medicine
proms
quality of life
antibiotics
cost-effectiveness
presentation
incentives
patients
health outcomes
health policy
value-based pricing
drugs
emerging markets
diagnostics
devlin
ispor europe 2018
indication-based pricing
intellectual property
pharmaceutical innovation
hepatitis c
discrete choice experiment
stated preferences
children
preferences
end of life
economics
decision modelling
İçer
eq-5d-y
patient-reported outcomes
access
antimicrobial resistance
amr
drug development
qalys
prescription drug
france
germany
costs
vbp
competition
research
euroqol
risperidone
net monetary benefit
life-cycle value
public preferences
2018
multi-indication pricing
research and development
measurement for drugs
affordability
utilities
orphan drugs
direct acting antivirals
adolescents
cost-effectiveness analysis
mental health
transparency
open source
presentations
health status
tto
health care systems
mlics
discrete choice
end-of-life
rare diseases
genomics
differential pricing
access to care
elderly
wellbeing
costa rica
prices
patient reported outcomes
value
medical research
quality
risk
public
asia
spillovers
policy
outcomes
dying
death
dead
health state valuation
health
poster
internet survey
generic competition
social surplus
second generation antipsychotics
italy
sweden
procurement
contracting
antipsychotics
surplus
innovative medicine
financial incentives
national health service
specialised care
pay-for-performance
payers
novel elements of value
real option value
hta decision making
mcda
weighted cea
augmented cea
weighted qalys
value in health
decision analysis
modeling
healthcare
data analytics
next generation sequencing
genomic testing
oncology
lung cancer
outcomes-based contracting
real world evidence
royal brompton
legitimate legal bases
consent
gdpr
health data
legal barriers
innovative payment models
indication specific pricing
indication based pricing
stated preference
professional training
health financing
universal health coverage
value of knowing
value of diagnostic information
third plenary session
expenditure caps
expenditure
impact
buget
indication-based-pricing
debate
ispor barcelona
welfare states
patient-centred care
fair pricing
world health organisation
heath technology assessment (hta)
globalisation
barcelona
ispor 2018
curative therapies
challenges
rewards
payors
regulators
triangulating developers
handling uncertainty
payment mechanisms
evidence uncertainty
hta outcomes
hta transferability
patient involvement
flexibility and transparency
hta lifecycle
therapeutic added value
future directions
modern hta
good practice
pharmaceutical r&d.
value-based pricing and reimbursement
pharmacoeconomics
multi-indication drugs
indication-specific pricing
washington dc
ispor summit
nancy devlin
qaly's
lou garrison
ipor washing dc
approaches to value assessment
labour productivity
learning outcomes
international volunteering
global engagement
price discrimination
indication
price and reimbursement
pharmaceutical regulation
market competition
health system capacity
daas
matching
mapping
uptake curves
static and dynamic efficiency
market access
r&d incentives
supplementary patent certificates
economics of r&d
rates of return
cost-effectiveness threshold
revenue
cost of r&d
fairness
qualitative analysis
interviews
uptake
economics of cures
methodology
visual analogue scale
time trade-off
valuation
markov
screening
diabetic retinopathy
real-world data
real-world evidence
vaccines
framing effects
clinical evaluation
systematic review
cadth
sustainability
proms conference
koonal shah
oncology medicines
outcome-based payments
tto valuations of health states
eq-5d-5l
eq-5d-3l
end of life medicines
koonal
healtcare decision making
cea
uhc
pbrsa
hip surgery
us
cost effectiveness
icer
uae
ed-5d
health care costs
pprs
ldcs
global health
mhra
ema
generics
biosimilars
latin america
end-of-life care
burden of illness
heor
time trade off
antimicrobials
resistance
antibacterials
personalized medicine
patient access schemes
public attitudes
caregiving
long-term care
technology
pharmaceutical
big data
stratified medicine
unmet need
aai
medicare
health insurance
usa
taiwan
china
brazil
health inequality
inequality
pharm
international comparisons
forecast
clinical trial
cost
assessment
australia
ispe
disease management
politics
commissioning
funding
kings fund
eq-vas
Tout plus
Présentations
(218)Documents
(45)J’aime
(1)Presentation layout tips
seandeetlefs
•
il y a 13 ans
Personal Information
Entreprise/Lieu de travail
London, United Kingdom United Kingdom
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
ohe.org
À propos
OHE provides authoritative resources and analyses in health economics, health policy and health statistics through independent research and consultancy. Our work informs decision making about health care, life sciences and the pharmaceutical industry, tackling policy and strategic issues affecting the present and shaping the future. We work closely with stakeholders, clients and external experts to develop important new policy insights, define strategies and identify optimal choices.
Mots-clés
health economics
hta
pharmaceuticals
uk
medicines
health care
innovation
eq-5d
nhs
pricing
biotechnology and pharmaceuticals
nice
htai
pharmaceutical industry
r&d
england
ohe
adrian towse
ispor
cancer
health technology assessment
reimbursement
qaly
europe
medicine
proms
quality of life
antibiotics
cost-effectiveness
presentation
incentives
patients
health outcomes
health policy
value-based pricing
drugs
emerging markets
diagnostics
devlin
ispor europe 2018
indication-based pricing
intellectual property
pharmaceutical innovation
hepatitis c
discrete choice experiment
stated preferences
children
preferences
end of life
economics
decision modelling
İçer
eq-5d-y
patient-reported outcomes
access
antimicrobial resistance
amr
drug development
qalys
prescription drug
france
germany
costs
vbp
competition
research
euroqol
risperidone
net monetary benefit
life-cycle value
public preferences
2018
multi-indication pricing
research and development
measurement for drugs
affordability
utilities
orphan drugs
direct acting antivirals
adolescents
cost-effectiveness analysis
mental health
transparency
open source
presentations
health status
tto
health care systems
mlics
discrete choice
end-of-life
rare diseases
genomics
differential pricing
access to care
elderly
wellbeing
costa rica
prices
patient reported outcomes
value
medical research
quality
risk
public
asia
spillovers
policy
outcomes
dying
death
dead
health state valuation
health
poster
internet survey
generic competition
social surplus
second generation antipsychotics
italy
sweden
procurement
contracting
antipsychotics
surplus
innovative medicine
financial incentives
national health service
specialised care
pay-for-performance
payers
novel elements of value
real option value
hta decision making
mcda
weighted cea
augmented cea
weighted qalys
value in health
decision analysis
modeling
healthcare
data analytics
next generation sequencing
genomic testing
oncology
lung cancer
outcomes-based contracting
real world evidence
royal brompton
legitimate legal bases
consent
gdpr
health data
legal barriers
innovative payment models
indication specific pricing
indication based pricing
stated preference
professional training
health financing
universal health coverage
value of knowing
value of diagnostic information
third plenary session
expenditure caps
expenditure
impact
buget
indication-based-pricing
debate
ispor barcelona
welfare states
patient-centred care
fair pricing
world health organisation
heath technology assessment (hta)
globalisation
barcelona
ispor 2018
curative therapies
challenges
rewards
payors
regulators
triangulating developers
handling uncertainty
payment mechanisms
evidence uncertainty
hta outcomes
hta transferability
patient involvement
flexibility and transparency
hta lifecycle
therapeutic added value
future directions
modern hta
good practice
pharmaceutical r&d.
value-based pricing and reimbursement
pharmacoeconomics
multi-indication drugs
indication-specific pricing
washington dc
ispor summit
nancy devlin
qaly's
lou garrison
ipor washing dc
approaches to value assessment
labour productivity
learning outcomes
international volunteering
global engagement
price discrimination
indication
price and reimbursement
pharmaceutical regulation
market competition
health system capacity
daas
matching
mapping
uptake curves
static and dynamic efficiency
market access
r&d incentives
supplementary patent certificates
economics of r&d
rates of return
cost-effectiveness threshold
revenue
cost of r&d
fairness
qualitative analysis
interviews
uptake
economics of cures
methodology
visual analogue scale
time trade-off
valuation
markov
screening
diabetic retinopathy
real-world data
real-world evidence
vaccines
framing effects
clinical evaluation
systematic review
cadth
sustainability
proms conference
koonal shah
oncology medicines
outcome-based payments
tto valuations of health states
eq-5d-5l
eq-5d-3l
end of life medicines
koonal
healtcare decision making
cea
uhc
pbrsa
hip surgery
us
cost effectiveness
icer
uae
ed-5d
health care costs
pprs
ldcs
global health
mhra
ema
generics
biosimilars
latin america
end-of-life care
burden of illness
heor
time trade off
antimicrobials
resistance
antibacterials
personalized medicine
patient access schemes
public attitudes
caregiving
long-term care
technology
pharmaceutical
big data
stratified medicine
unmet need
aai
medicare
health insurance
usa
taiwan
china
brazil
health inequality
inequality
pharm
international comparisons
forecast
clinical trial
cost
assessment
australia
ispe
disease management
politics
commissioning
funding
kings fund
eq-vas
Tout plus